The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors

Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold great clinical potential. Very recently, a drug targeting the K-Ras(G12C) mutant observed in lung cancer gained regulatory approval and several clinical t...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; p. 8121
Main Authors Sakamoto, Kotaro, Lin, Bangzhong, Nunomura, Kazuto, Izawa, Takeshi, Nakagawa, Shinsaku
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 17.05.2022
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold great clinical potential. Very recently, a drug targeting the K-Ras(G12C) mutant observed in lung cancer gained regulatory approval and several clinical trials are currently underway to examine the efficacy of this agent when combined with other drugs such as a monoclonal antibody inhibitor of programmed cell death 1 receptor (anti-PD-1). Alternatively, there are currently no approved drugs targeting K-Ras(G12D), the most common cancer-associated K-Ras mutant. In 2020, we described the development of the K-Ras(G12D) inhibitory bicyclic peptide KS-58 and presented evidence for anticancer activity against mouse xenografts derived from the human pancreatic cancer cell line PANC-1 stably expressing K-Ras(G12D). Here, we show that KS-58 also possess anticancer activity against mouse tumors derived from the colorectal cancer cell line CT26 stably expressing K-Ras(G12D). Further, KS-58 treatment reduced phosphorylation of ERK, a major downstream signaling factor in the Ras pathway, confirming that KS-58 inhibits K-Ras(G12D) function. Unexpectedly; however, KS-58 did not show additive or synergistic anticancer activity with mouse anti-PD-1. Morphological analysis and immunostaining demonstrated no obvious differences in CD8 + cells infiltration or PD-L1 expression levels in CT26-derived tumors exposed to monotherapy or combination treatment. Nonetheless, KS-58 demonstrated reasonable stability in blood ( t 1/2 ≈ 30 min) and no obvious systemic adverse effects, suggesting clinical potential as a lead molecule against colorectal cancer.
AbstractList Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold great clinical potential. Very recently, a drug targeting the K-Ras(G12C) mutant observed in lung cancer gained regulatory approval and several clinical trials are currently underway to examine the efficacy of this agent when combined with other drugs such as a monoclonal antibody inhibitor of programmed cell death 1 receptor (anti-PD-1). Alternatively, there are currently no approved drugs targeting K-Ras(G12D), the most common cancer-associated K-Ras mutant. In 2020, we described the development of the K-Ras(G12D) inhibitory bicyclic peptide KS-58 and presented evidence for anticancer activity against mouse xenografts derived from the human pancreatic cancer cell line PANC-1 stably expressing K-Ras(G12D). Here, we show that KS-58 also possess anticancer activity against mouse tumors derived from the colorectal cancer cell line CT26 stably expressing K-Ras(G12D). Further, KS-58 treatment reduced phosphorylation of ERK, a major downstream signaling factor in the Ras pathway, confirming that KS-58 inhibits K-Ras(G12D) function. Unexpectedly; however, KS-58 did not show additive or synergistic anticancer activity with mouse anti-PD-1. Morphological analysis and immunostaining demonstrated no obvious differences in CD8 + cells infiltration or PD-L1 expression levels in CT26-derived tumors exposed to monotherapy or combination treatment. Nonetheless, KS-58 demonstrated reasonable stability in blood ( t 1/2 ≈ 30 min) and no obvious systemic adverse effects, suggesting clinical potential as a lead molecule against colorectal cancer.
Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold great clinical potential. Very recently, a drug targeting the K-Ras(G12C) mutant observed in lung cancer gained regulatory approval and several clinical trials are currently underway to examine the efficacy of this agent when combined with other drugs such as a monoclonal antibody inhibitor of programmed cell death 1 receptor (anti-PD-1). Alternatively, there are currently no approved drugs targeting K-Ras(G12D), the most common cancer-associated K-Ras mutant. In 2020, we described the development of the K-Ras(G12D) inhibitory bicyclic peptide KS-58 and presented evidence for anticancer activity against mouse xenografts derived from the human pancreatic cancer cell line PANC-1 stably expressing K-Ras(G12D). Here, we show that KS-58 also possess anticancer activity against mouse tumors derived from the colorectal cancer cell line CT26 stably expressing K-Ras(G12D). Further, KS-58 treatment reduced phosphorylation of ERK, a major downstream signaling factor in the Ras pathway, confirming that KS-58 inhibits K-Ras(G12D) function. Unexpectedly; however, KS-58 did not show additive or synergistic anticancer activity with mouse anti-PD-1. Morphological analysis and immunostaining demonstrated no obvious differences in CD8+ cells infiltration or PD-L1 expression levels in CT26-derived tumors exposed to monotherapy or combination treatment. Nonetheless, KS-58 demonstrated reasonable stability in blood (t1/2 ≈ 30 min) and no obvious systemic adverse effects, suggesting clinical potential as a lead molecule against colorectal cancer.
Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold great clinical potential. Very recently, a drug targeting the K-Ras(G12C) mutant observed in lung cancer gained regulatory approval and several clinical trials are currently underway to examine the efficacy of this agent when combined with other drugs such as a monoclonal antibody inhibitor of programmed cell death 1 receptor (anti-PD-1). Alternatively, there are currently no approved drugs targeting K-Ras(G12D), the most common cancer-associated K-Ras mutant. In 2020, we described the development of the K-Ras(G12D) inhibitory bicyclic peptide KS-58 and presented evidence for anticancer activity against mouse xenografts derived from the human pancreatic cancer cell line PANC-1 stably expressing K-Ras(G12D). Here, we show that KS-58 also possess anticancer activity against mouse tumors derived from the colorectal cancer cell line CT26 stably expressing K-Ras(G12D). Further, KS-58 treatment reduced phosphorylation of ERK, a major downstream signaling factor in the Ras pathway, confirming that KS-58 inhibits K-Ras(G12D) function. Unexpectedly; however, KS-58 did not show additive or synergistic anticancer activity with mouse anti-PD-1. Morphological analysis and immunostaining demonstrated no obvious differences in CD8 cells infiltration or PD-L1 expression levels in CT26-derived tumors exposed to monotherapy or combination treatment. Nonetheless, KS-58 demonstrated reasonable stability in blood (t ≈ 30 min) and no obvious systemic adverse effects, suggesting clinical potential as a lead molecule against colorectal cancer.
Abstract Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold great clinical potential. Very recently, a drug targeting the K-Ras(G12C) mutant observed in lung cancer gained regulatory approval and several clinical trials are currently underway to examine the efficacy of this agent when combined with other drugs such as a monoclonal antibody inhibitor of programmed cell death 1 receptor (anti-PD-1). Alternatively, there are currently no approved drugs targeting K-Ras(G12D), the most common cancer-associated K-Ras mutant. In 2020, we described the development of the K-Ras(G12D) inhibitory bicyclic peptide KS-58 and presented evidence for anticancer activity against mouse xenografts derived from the human pancreatic cancer cell line PANC-1 stably expressing K-Ras(G12D). Here, we show that KS-58 also possess anticancer activity against mouse tumors derived from the colorectal cancer cell line CT26 stably expressing K-Ras(G12D). Further, KS-58 treatment reduced phosphorylation of ERK, a major downstream signaling factor in the Ras pathway, confirming that KS-58 inhibits K-Ras(G12D) function. Unexpectedly; however, KS-58 did not show additive or synergistic anticancer activity with mouse anti-PD-1. Morphological analysis and immunostaining demonstrated no obvious differences in CD8+ cells infiltration or PD-L1 expression levels in CT26-derived tumors exposed to monotherapy or combination treatment. Nonetheless, KS-58 demonstrated reasonable stability in blood (t 1/2 ≈ 30 min) and no obvious systemic adverse effects, suggesting clinical potential as a lead molecule against colorectal cancer.
ArticleNumber 8121
Author Izawa, Takeshi
Nunomura, Kazuto
Sakamoto, Kotaro
Lin, Bangzhong
Nakagawa, Shinsaku
Author_xml – sequence: 1
  givenname: Kotaro
  surname: Sakamoto
  fullname: Sakamoto, Kotaro
  email: sakamoto-kotaro@ichimaru.co.jp
  organization: Research & Development Department, Ichimaru Pharcos Company Limited
– sequence: 2
  givenname: Bangzhong
  surname: Lin
  fullname: Lin, Bangzhong
  organization: Center for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Science, Osaka University
– sequence: 3
  givenname: Kazuto
  surname: Nunomura
  fullname: Nunomura, Kazuto
  organization: Center for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Science, Osaka University
– sequence: 4
  givenname: Takeshi
  surname: Izawa
  fullname: Izawa, Takeshi
  organization: Laboratory of Veterinary Pathology, Osaka Prefecture University
– sequence: 5
  givenname: Shinsaku
  surname: Nakagawa
  fullname: Nakagawa, Shinsaku
  organization: Center for Supporting Drug Discovery and Life Science Research, Graduate School of Pharmaceutical Science, Osaka University, Laboratory of Biopharmaceutics, Osaka University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35581303$$D View this record in MEDLINE/PubMed
BookMark eNp9ksFvFCEUxiemxtbaf8CDIfFSDyjwYIa5mDSr1sYmJrqeCQPMLpvZYYSZmv73Mju1th7kAuH73o_Hy_e8OOpD74riJSVvKQH5LnEqaokJY5gyTiiGJ8UJI1xgBowdPTgfF2cp7UhegtWc1s-KYxBCUiBwUoT11qEv-JtO55eUfXiDfb_1jR9DvEWDG0Zvs_wdC4nSNAzRpeQS2sTwa9yi0KL9FH3v0GrNSmRCF6Izo-6Q0b1xERnXddi66G-cReO0DzG9KJ62ukvu7G4_LX58-rhefcbXXy-vVhfX2AhORgyS84a3rSxB2LlzXZncMBWgoeQuawZIw4yVwracNbx2Ta1bClTIsiUWTourhWuD3qkh-r2Otyporw4XIW6UjqM3nVOi5JXklTCElJwxIYkEA5Y2rAHbsCqz3i-sYWr2zhrXj1F3j6CPld5v1SbcqJpSDpJlwPkdIIafk0uj2vs0D0f3LkxJsbIsBa_Iwfr6H-suTLHPo5pdglOAeu6ILS4TQ0rRtffNUKLmeKglHirHQx3ioSAXvXr4jfuSP2HIBlgMKUv9xsW_b_8H-xuGUMSG
CitedBy_id crossref_primary_10_3389_fbioe_2023_1279473
crossref_primary_10_1186_s12967_023_04619_0
crossref_primary_10_1016_j_bmcl_2024_129649
crossref_primary_10_1016_j_yao_2023_01_011
crossref_primary_10_3390_cancers16101808
crossref_primary_10_1038_s41598_023_27825_8
crossref_primary_10_3390_cancers15092570
crossref_primary_10_1158_1940_6207_CAPR_23_0015
crossref_primary_10_1016_j_fbio_2024_103903
crossref_primary_10_1042_BST20221343
crossref_primary_10_3390_pharmaceutics15061686
Cites_doi 10.1038/s41467-021-22969-5
10.3390/ijms22063025
10.1021/acs.biochem.7b00271
10.1016/j.ccell.2021.07.023
10.1016/j.apsb.2018.08.009
10.1186/1471-2164-15-190
10.3390/genes12060899
10.1016/j.bbrc.2017.01.147
10.1038/s41467-021-22875-w
10.1038/s41586-019-1694-1
10.1126/sciimmunol.aav3937
10.1038/ncomms16092
10.1158/0008-5472.CAN-11-2612
10.1021/acsmedchemlett.7b00128
10.1111/bph.12955
10.1111/j.1476-5381.2010.00872.x
10.1038/s41573-020-0068-6
10.1016/j.lungcan.2021.07.005
10.1158/1535-7163.MCT-20-0462
10.1038/s41598-020-78712-5
10.1016/j.bmcl.2017.04.063
10.1038/s41467-020-17648-w
10.3389/fonc.2019.01088
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PIMPY
PQEST
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-022-12401-3
DatabaseName SpringerOpen
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Science Database
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
Publicly Available Content Database


MEDLINE

Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 8121
ExternalDocumentID oai_doaj_org_article_56478475c00642258083c3d1b2b3db27
10_1038_s41598_022_12401_3
35581303
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ADBBV
ADRAZ
AENEX
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RIG
RNT
RNTTT
RPM
SNYQT
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7XB
8FK
K9.
PQEST
PQUKI
Q9U
7X8
5PM
AFPKN
ID FETCH-LOGICAL-c540t-3844b4ff8635d0005a7c130153a364e4b4c30b2cd85df42b49eb9af131586f0d3
IEDL.DBID RPM
ISSN 2045-2322
IngestDate Tue Nov 26 07:56:45 EST 2024
Tue Sep 17 21:15:03 EDT 2024
Wed Dec 04 14:17:01 EST 2024
Sat Nov 09 10:47:49 EST 2024
Fri Dec 06 04:24:06 EST 2024
Wed Oct 16 00:39:54 EDT 2024
Fri Oct 11 20:56:07 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-3844b4ff8635d0005a7c130153a364e4b4c30b2cd85df42b49eb9af131586f0d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114382/
PMID 35581303
PQID 2665413397
PQPubID 2041939
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_56478475c00642258083c3d1b2b3db27
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9114382
proquest_miscellaneous_2666547082
proquest_journals_2665413397
crossref_primary_10_1038_s41598_022_12401_3
pubmed_primary_35581303
springer_journals_10_1038_s41598_022_12401_3
PublicationCentury 2000
PublicationDate 2022-05-17
PublicationDateYYYYMMDD 2022-05-17
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-17
  day: 17
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Moore, Roseberg, McCormick, Malek (CR8) 2020; 19
(CR15) 1996
Maldonado, Zimmer, Medová (CR1) 2019; 9
Teng, Tsai, Hattori, Fedele, Koide, Yang, Hou, Zhang, Neel, O'Bryan, Koide (CR10) 2021; 12
Zhao, Guo, Wu, Yang, Zhong, Deng, Zhu, Liu, Gu, Lu, Kong, Meng, Xu, Sun (CR22) 2019; 9
Sogabe, Kamada, Miwa, Niida, Sameshima, Kamaura, Yonemori, Sasaki, Sakamoto, Sakamoto (CR13) 2017; 8
Castle, Loewer, Boegel, Graaf, Bender, Tadmor, Boisguerin, Bukur, Sorn, Paret, Diken, Kreiter, Türeci, Sahin (CR18) 2014; 15
Wilbs, Kong, Middendorp, Prince, Cooke, Demarest, Abdelhafez, Roberts, Umei, Gonschorek, Lamers, Deyle, Rieben, Cook, Angelillo-Scherrer, Heinis (CR23) 2020; 11
Briere, Li, Calinisan, Sudhakar, Aranda, Hargis, Hargis, Peng, Geng, Engstrom, Hallin, Gatto, Fernandez-Banet, Pavlicek, Wong, Christensen, Olson (CR5) 2021; 20
Niida, Sasaki, Yonemori, Sameshima, Yaguchi, Asami, Sakamoto, Kamaura (CR12) 2017; 27
Peng, Rodriguez, Diao, Gaudreau, Padhye, Konen, Ochieng, Class, Fradette, Gibson, Chen, Wang, Byers, Gibbons (CR19) 2021; 12
Lindsay, Garassino, Nadal, Öhrling, Scheffler, Khan (CR3) 2021; 160
Kilkenny, Browne, Cuthill, Emerson, Altman (CR17) 2010; 160
Sakamoto, Masutani, Hirokawa (CR14) 2020; 10
Qzorzi, Middendorp, Wilbs, Deyle, Heinis (CR24) 2017; 8
Köhler, Jänne (CR4) 2021; 22
Prior, Lewis, Mattos (CR7) 2012; 72
McGregor, Jenkins, Kerwin, Burke, Shokat (CR9) 2017; 56
Wang, Liu, Yang, Algazi, Lomeli, Wang, Othus, Hong, Wang, Randolph, Jones, Bosenberg, Byrum, Tackett, Lopez, Yates, Solit, Ribas, Piva, Moriceau, Lo (CR20) 2021; 39
Sugiyama, Togashi, Takeuchi, Shinya, Tada, Kataoka, Tane, Sato, Ishii, Goto, Shintani, Okumura, Tsuboi, Nishikawa (CR21) 2020; 5
Canon, Rex, Saiki, Mohr, Cooke, Bagal, Gaida, Holt, Knutson, Koppada, Lanman, Werner, Rapaport, Miguel, Ortiz, Osgood, Sun, Zhu, McCarter, Volak, Houk, Fakih, O’Neil, Price, Falchook, Desai, Kuo, Govindan, Hong, Ouyang, Henary, Arvedson, Cee, Lipford (CR2) 2019; 575
Sakamoto, Kamada, Sameshima, Yaguchi, Niida, Sasaki, Miwa, Ohkubo, Sakamoto, Kamaura, Cho, Tani (CR11) 2017; 484
Molina-Arcas, Samani, Downward (CR6) 2021; 12
McGrath, Lilley (CR16) 2015; 172
ML McGregor (12401_CR9) 2017; 56
A Qzorzi (12401_CR24) 2017; 8
J Canon (12401_CR2) 2019; 575
WK Teng (12401_CR10) 2021; 12
JC Castle (12401_CR18) 2014; 15
E Sugiyama (12401_CR21) 2020; 5
K Sakamoto (12401_CR14) 2020; 10
HD Peng (12401_CR19) 2021; 12
J Köhler (12401_CR4) 2021; 22
MD Briere (12401_CR5) 2021; 20
AI Prior (12401_CR7) 2012; 72
RA Moore (12401_CR8) 2020; 19
RC Lindsay (12401_CR3) 2021; 160
MC Maldonado (12401_CR1) 2019; 9
M Molina-Arcas (12401_CR6) 2021; 12
National Research Council (US) Institute for Laboratory Animal Research (12401_CR15) 1996
JC McGrath (12401_CR16) 2015; 172
K Sakamoto (12401_CR11) 2017; 484
S Sogabe (12401_CR13) 2017; 8
C Kilkenny (12401_CR17) 2010; 160
A Niida (12401_CR12) 2017; 27
J Wilbs (12401_CR23) 2020; 11
Y Wang (12401_CR20) 2021; 39
M Zhao (12401_CR22) 2019; 9
References_xml – volume: 12
  start-page: 2656
  year: 2021
  ident: CR10
  article-title: Selective and noncovalent targeting of Ras mutants for inhibition and degradation
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22969-5
  contributor:
    fullname: Koide
– volume: 22
  start-page: 3025
  year: 2021
  ident: CR4
  article-title: If Virchow and Ehrlich had dreamt together: What the future holds for -mutant lung cancer
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22063025
  contributor:
    fullname: Jänne
– volume: 56
  start-page: 3178
  year: 2017
  end-page: 3183
  ident: CR9
  article-title: Expanding the scope of electrophiles capable of targeting K-RAS oncogenes
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.7b00271
  contributor:
    fullname: Shokat
– volume: 39
  start-page: 1375
  year: 2021
  ident: CR20
  article-title: Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.07.023
  contributor:
    fullname: Lo
– volume: 9
  start-page: 304
  year: 2019
  end-page: 315
  ident: CR22
  article-title: SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2018.08.009
  contributor:
    fullname: Sun
– volume: 15
  start-page: 190
  year: 2014
  ident: CR18
  article-title: Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-15-190
  contributor:
    fullname: Sahin
– volume: 12
  start-page: 899
  year: 2021
  ident: CR6
  article-title: Drugging the undruggable: Advances on RAS targeting in cancer
  publication-title: Genes
  doi: 10.3390/genes12060899
  contributor:
    fullname: Downward
– volume: 484
  start-page: 605
  year: 2017
  end-page: 611
  ident: CR11
  article-title: K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2017.01.147
  contributor:
    fullname: Tani
– year: 1996
  ident: CR15
  publication-title: Guide for the Care and Use of Laboratory Animals
– volume: 12
  start-page: 2606
  year: 2021
  ident: CR19
  article-title: Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22875-w
  contributor:
    fullname: Gibbons
– volume: 575
  start-page: 217
  year: 2019
  end-page: 223
  ident: CR2
  article-title: The clinical KRAS(G12C) inhibitor amg 510 drives anti-tumor immunity
  publication-title: Nature
  doi: 10.1038/s41586-019-1694-1
  contributor:
    fullname: Lipford
– volume: 5
  start-page: 3937
  year: 2020
  ident: CR21
  article-title: Blockade of EGFR improves responsiveness to PD-1 blockade in -mutated non-small cell lung cancer
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.aav3937
  contributor:
    fullname: Nishikawa
– volume: 8
  start-page: 16092
  year: 2017
  ident: CR24
  article-title: Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms16092
  contributor:
    fullname: Heinis
– volume: 72
  start-page: 2457
  year: 2012
  end-page: 2467
  ident: CR7
  article-title: A Comprehensive survey of Ras mutations in cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-11-2612
  contributor:
    fullname: Mattos
– volume: 8
  start-page: 732
  year: 2017
  end-page: 736
  ident: CR13
  article-title: Crystal structure of a human K-Ras G12D mutant in complex with GDP and the cyclic inhibitory peptide KRpep-2d
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/acsmedchemlett.7b00128
  contributor:
    fullname: Sakamoto
– volume: 172
  start-page: 3189
  year: 2015
  end-page: 3193
  ident: CR16
  article-title: Implementing guidelines on reporting research using animals (ARRIVE etc): New requirements for publication in BJP
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12955
  contributor:
    fullname: Lilley
– volume: 160
  start-page: 1577
  year: 2010
  end-page: 1579
  ident: CR17
  article-title: NC3Rs Reporting Guidelines Working Group, animal research: Reporting in vivo experiments: The ARRIVE guidelines
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/j.1476-5381.2010.00872.x
  contributor:
    fullname: Altman
– volume: 19
  start-page: 533
  year: 2020
  end-page: 552
  ident: CR8
  article-title: RAS-targeted therapies: Is the undruggable drugged?
  publication-title: Nat. Rev. Drug. Discov.
  doi: 10.1038/s41573-020-0068-6
  contributor:
    fullname: Malek
– volume: 160
  start-page: 152
  year: 2021
  ident: CR3
  article-title: On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2021.07.005
  contributor:
    fullname: Khan
– volume: 20
  start-page: 975
  year: 2021
  end-page: 985
  ident: CR5
  article-title: The KRAS Inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0462
  contributor:
    fullname: Olson
– volume: 10
  start-page: 21671
  year: 2020
  ident: CR14
  article-title: Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-78712-5
  contributor:
    fullname: Hirokawa
– volume: 27
  start-page: 2757
  year: 2017
  end-page: 2761
  ident: CR12
  article-title: Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2017.04.063
  contributor:
    fullname: Kamaura
– volume: 11
  start-page: 3890
  year: 2020
  ident: CR23
  article-title: Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-17648-w
  contributor:
    fullname: Heinis
– volume: 9
  start-page: 1088
  year: 2019
  ident: CR1
  article-title: A comparative analysis of individual RAS mutations in cancer biology
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.01088
  contributor:
    fullname: Medová
– volume: 9
  start-page: 1088
  year: 2019
  ident: 12401_CR1
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.01088
  contributor:
    fullname: MC Maldonado
– volume: 20
  start-page: 975
  year: 2021
  ident: 12401_CR5
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0462
  contributor:
    fullname: MD Briere
– volume: 22
  start-page: 3025
  year: 2021
  ident: 12401_CR4
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22063025
  contributor:
    fullname: J Köhler
– volume-title: Guide for the Care and Use of Laboratory Animals
  year: 1996
  ident: 12401_CR15
  contributor:
    fullname: National Research Council (US) Institute for Laboratory Animal Research
– volume: 12
  start-page: 2606
  year: 2021
  ident: 12401_CR19
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22875-w
  contributor:
    fullname: HD Peng
– volume: 39
  start-page: 1375
  year: 2021
  ident: 12401_CR20
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.07.023
  contributor:
    fullname: Y Wang
– volume: 9
  start-page: 304
  year: 2019
  ident: 12401_CR22
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2018.08.009
  contributor:
    fullname: M Zhao
– volume: 10
  start-page: 21671
  year: 2020
  ident: 12401_CR14
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-78712-5
  contributor:
    fullname: K Sakamoto
– volume: 5
  start-page: 3937
  year: 2020
  ident: 12401_CR21
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.aav3937
  contributor:
    fullname: E Sugiyama
– volume: 12
  start-page: 899
  year: 2021
  ident: 12401_CR6
  publication-title: Genes
  doi: 10.3390/genes12060899
  contributor:
    fullname: M Molina-Arcas
– volume: 15
  start-page: 190
  year: 2014
  ident: 12401_CR18
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-15-190
  contributor:
    fullname: JC Castle
– volume: 484
  start-page: 605
  year: 2017
  ident: 12401_CR11
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2017.01.147
  contributor:
    fullname: K Sakamoto
– volume: 12
  start-page: 2656
  year: 2021
  ident: 12401_CR10
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22969-5
  contributor:
    fullname: WK Teng
– volume: 8
  start-page: 732
  year: 2017
  ident: 12401_CR13
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/acsmedchemlett.7b00128
  contributor:
    fullname: S Sogabe
– volume: 160
  start-page: 152
  year: 2021
  ident: 12401_CR3
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2021.07.005
  contributor:
    fullname: RC Lindsay
– volume: 11
  start-page: 3890
  year: 2020
  ident: 12401_CR23
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-17648-w
  contributor:
    fullname: J Wilbs
– volume: 19
  start-page: 533
  year: 2020
  ident: 12401_CR8
  publication-title: Nat. Rev. Drug. Discov.
  doi: 10.1038/s41573-020-0068-6
  contributor:
    fullname: RA Moore
– volume: 575
  start-page: 217
  year: 2019
  ident: 12401_CR2
  publication-title: Nature
  doi: 10.1038/s41586-019-1694-1
  contributor:
    fullname: J Canon
– volume: 72
  start-page: 2457
  year: 2012
  ident: 12401_CR7
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-11-2612
  contributor:
    fullname: AI Prior
– volume: 56
  start-page: 3178
  year: 2017
  ident: 12401_CR9
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.7b00271
  contributor:
    fullname: ML McGregor
– volume: 172
  start-page: 3189
  year: 2015
  ident: 12401_CR16
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12955
  contributor:
    fullname: JC McGrath
– volume: 27
  start-page: 2757
  year: 2017
  ident: 12401_CR12
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2017.04.063
  contributor:
    fullname: A Niida
– volume: 160
  start-page: 1577
  year: 2010
  ident: 12401_CR17
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/j.1476-5381.2010.00872.x
  contributor:
    fullname: C Kilkenny
– volume: 8
  start-page: 16092
  year: 2017
  ident: 12401_CR24
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms16092
  contributor:
    fullname: A Qzorzi
SSID ssj0000529419
Score 2.4710503
Snippet Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold great...
Abstract Mutations in the cell proliferation regulator K-Ras are found with a variety of cancer types, so drugs targeting these mutant proteins could hold...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 8121
SubjectTerms 631/154
631/154/1438
631/154/436
631/154/556
631/154/570
631/67
631/67/1059
631/67/1504
631/67/395
Animals
Antitumor activity
Apoptosis
CD8 antigen
Cell death
Cell Line, Tumor
Cell Proliferation
Clinical trials
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Drug delivery
Humanities and Social Sciences
K-Ras protein
Lung cancer
Metastases
Mice
Monoclonal antibodies
multidisciplinary
Mutant Proteins - genetics
Mutants
Mutation
Pancreatic cancer
PD-1 protein
PD-L1 protein
Peptides
Peptides - therapeutic use
Phosphorylation
Proto-Oncogene Proteins p21(ras) - genetics
Regulatory approval
Science
Science (multidisciplinary)
Tumors
Xenografts
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuCCiPlIKMxAEEVhPbSZxjW1oqkDhAK_Vm2bHN7qHJapOt1H_PjJ1dujzEhWvGUqyZz54Ze_wNIa-LwoFlYferDSxyyBgaZnzZMqMMOM9Q-cLHAtkv1dmF_HRZXt5q9YU1YYkeOCnuoMTHkLIuW3SeAD4FMUMrXGG5Fc7y9I4857eSqcTqzRtZNNMrmVyogwE8Fb4m49jLA5IKJrY8USTs_1OU-Xux5C83ptERnT4g96cIkh6mmT8kd3z3iNxNPSVvdkkPhqef2VczvPlY8A9v2bybze0c79LpAktYHIi_sVLRYbWIVbB-oN8hGR9ntA_0Ck_fPT0-5xVFQmvcEOFvLYJjSfGYnzkA7bV3dFxd9cvhMbk4PTk_PmNTVwXWQnQ2MqGktDIEBaGGQ02ZugVHBjufEZX0IGtFbnnrVOmC5FY23jYmFKIoVRVyJ56Qna7v_DNCpYPgLDS2sgFZ3HMlhW947XPjasF9yMi7tYb1IpFn6HjpLZRO9tBgDx3toUVGjtAIm5FIfB0_ABz0BAf9LzhkZH9tQj2txkFzbLEMyXgD4lcbMawj1JrpfL-KY7APM0REGXmaLL6ZCVLQo6_PSL2Fha2pbku6-SxydYMvwavWjLxfo-bntP6uir3_oYrn5B5HuCPVbL1Pdsblyr-ACGq0L-Ni-QE29hG9
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k2gICNxAIHVxHZi54SgUCqQOEAr7c2yY7u7hybLJlup_54ZJ7vV8rpmIsXxvD7PjGcIeVkUHjgL1k9ZUHI4MdTMhrJhVltwnrEKRUgFst-q41P5ZVbOpoBbP5VVbmxiMtS-azBGfsBxTC4cqGr1bvmT4dQozK5OIzSukxsFB1cO8qxmahtjwSyWLOrprkwu9EEP_grvlHGc6AFHCyZ2_FFq2_83rPlnyeRvedPkjo7ukNsTjqTvR8bfJddCe4_cHCdLXt4nHbCffmXfbf_qc8E_vmaLdr5wC8yo0yUWsngg_2Clpv16mWphQ0_P4Eg-zGkX6TnG4AM9POEVxbbWaBbhaw2KyIpisJ95EN2L4OmwPu9W_QNyevTp5PCYTbMVWAMYbWBCS-lkjBoAh8edsqoBdwb2z4pKBqA1Ine88br0UXIn6-BqGwtRlLqKuRcPyV7bteExodIDRIu1q1zEXu65liLUXIXceiV4iBl5s9lhsxxbaJiU-hbajPwwwA-T-GFERj4gE7ZvYvvr9KBbnZlJm0yJN2SlKhtEVGCRNADJRvjCcSe84yoj-xsWmkkne3MlQRl5sSWDNuGu2TZ06_QOTmMGXJSRRyPHtyvBRvTo8TOidmRhZ6m7lHYxTx27waNgwjUjbzdSc7Wsf2_Fk___xVNyi6MgYytZtU_2htU6PAOENLjnSQ1-AawuCx0
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKERIXxJuUgozEAQSGje0kzgEhKJQKBAfoSr1Zdmx3V6LJNski-u-ZcbKLFpYD10y0a83D8zkz_oaQx2nqwLKw-xUGghxODCUzPquYUQaSZ8h96mOD7Jf8aCo_nmQnO2Q17mhUYLf1aIfzpKbt9xc_zy9eQ8C_Gq6Mq5cdJCG8KMZxTAecF5i4RC5zyIzY4vV5hPsD1zcvZZz1gSTsDMAEH-_RbP-ZjVwVKf234dC_2yn_qKnGVHV4nVwbMSZ9MzjFDbLj65vkyjB18uIWacA16Cf21XRPPqT83VM2r2dzO8dqO11gk4sD8TeWKdotF7FP1nf0FI7r_Yw2gZ7h93lPD455TpHyGrdM-LcK3aelWAhgDtz6h3e0X541bXebTA_fHx8csXHuAqsAv_VMKCmtDEEBGHGoNVNUkOpgbzQilx5klZhYXjmVuSC5laW3pQmpSDOVh4kTd8hu3dT-HqHSAXwLpc1tQJ73iZLCl7zwE-MKwX1IyLOVhvVioNfQsSwulB7socEeOtpDi4S8RSOs30Rq7PigaU_1GGk6w9uzssgqRFuwWykAmZVwqeVWOMuLhOyvTKhX7qY5DmGG43oJ4kdrMUQaas3UvlnGd3BSM2CmhNwdLL5eCZLUIxpISLHhCxtL3ZTU81lk84Zsg8XYhDxfec3vZf1bFXv_pbj75CpHv0bW2WKf7Pbt0j8AMNXbhzFCfgGeLhPW
  priority: 102
  providerName: Scholars Portal
– databaseName: SpringerOpen
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELWgCIkLKt-hBRmJAwgsNrYTO8d2oVQgcYBW6s2yY5vdQ5PVJovUf98ZJ7soUA5cdxyt5TfjefaMZwh5necekIXdT1kwcjgxVMyGomZWW3CesQx5SAmy38rTc_nlorgYy-TgW5hJ_F7oDx04GHwExrEFB5wFmLhN7oAPVqjN83K-u0_BiJXMq_FdzM2fTnxPKtF_E6_8Oz3yjxhpcj0n--T-yBnp0QDyA3IrNA_J3aGL5NUj0gLU9Cv7brs3n3P-8S1bNoulW2L0nK4wacWD-AcrNO02q5T3Gjr6E47f_YK2kV7ifXug8zNeUixhjVsg_FuN6rCmeLHPPKjpr-Bpv7ls191jcn7y6Wx-ysY-CqwGPtYzoaV0MkYN5MLjSllVg-uCvc6KUgaQ1WLmeO114aPkTlbBVTbmIi90GWdePCF7TduEZ4RKD3QsVq50Eeu2z7QUoeIqzKxXgoeYkXfbFTaroVyGSWFuoc2AhwE8TMLDiIwcIwi7kVjqOv0AGmBGyzEFvoaVqqiRPcHuo4E01sLnjjvhHVcZOdxCaEb76wzHpspw_K5A_GonBsvBVbNNaDdpDHZeBg6UkacD4ruZYNF59O4ZURNdmEx1KmmWi1SdG7wHBlcz8n6rNb-n9e-leP5_ww_IPY6KjWVk1SHZ69eb8ALYUe9eJrO4BltUA-0
  priority: 102
  providerName: Springer Nature
Title The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors
URI https://link.springer.com/article/10.1038/s41598-022-12401-3
https://www.ncbi.nlm.nih.gov/pubmed/35581303
https://www.proquest.com/docview/2665413397
https://search.proquest.com/docview/2666547082
https://pubmed.ncbi.nlm.nih.gov/PMC9114382
https://doaj.org/article/56478475c00642258083c3d1b2b3db27
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEF_aiuCL1O_Yeqzgg6LpJbubZPNoY2tRWkpt4d5C9iO9gJccl5zgf-_MJjk9P158OchNIMvMb752Z2cIeRWGBiQL1i8pQMkhY0j9wkbaL2QBzrOMbWhdgexFfHYjPs2i2Q6Jxrswrmhfq-qo_ro4qqu5q61cLvR0rBObXp5noKB4fjXdJbvgfn9J0fuG3iwVYTpckAm4nLbgpPAiGcMxHpBP-Dg8B9uKo_3e8keubf_fYs0_SyZ_Ozd17uh0n9wf4kj6vl_vA7Jj64fkbj9Z8vsj0oD46Wf_qmhffwzZhzd-Vc8rVeGJOl1iIYsB8hc_krRdL10trG3pLaTk3Zw2JV3gHryl2TWLKba1RrMIX9MIkRXFzX7fAHS_WUO79aJZtY_JzenJdXbmD7MVfA0xWudzKYQSZSkh4DDItCLRwA6wfwWPhQWa5oFi2sjIlIIpkVqVFmXIw0jGZWD4E7JXN7V9RqgwEKKVqYpVib3cAym4TVlig8IknNnSI29HDufLvoVG7o6-ucx70eQgmtyJJuceOUYhbN7E9tfuj2Z1mw8gyCO8ISuSSGNEBRZJQiCpuQkVU9wolnjkcBRhPuhkmzMctAwpeQrklxsyaBNyrahts3bv4DRmiIs88rSX-GYlI2I8kmxhYWup2xQAsOvYPQDWI-9G1Pxc1r9Z8fy_P3RA7jGEO3aZTQ7JXrda2xcQPHVqAiozSybkzvHJxeUVPGVxNnEbEfB7LuTEKdMPNy8ZNA
link.rule.ids 230,314,727,780,784,864,885,2102,12056,21388,24318,27924,27925,31719,31720,33744,33745,41120,42189,43310,43805,51576,53791,53793,73745,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9BJwQviM-RMcBIPIDAWmI7X0-IjY3CRoVGJ-3NimN77cOSrkmR-O-5S9NO5es1FymO7-vnu_MdwKsosshZtH5pgUqOJ4acFy4ueZEV6Dx94iLXFciOkuGZ-nIen_cBt6Yvq1zZxM5Q27qkGPmeoDG5eKDK0_ezK05Toyi72o_QuAlb1Dk9HsDW_uHo2-k6ykJ5LBXl_W2ZUGZ7DXosulUmaKYHHi643PBIXeP-v6HNP4smf8ucdg7p6B7c7ZEk-7Bk_X244aoHcGs5W_LnQ6hRANgxPy2a158i8fENn1aTqZlSTp3NqJTFIvk7jzPWLGZdNaxr2AUeytsJqz27pCi8YwdjkTBqbE2GEb9WkpDMGYX7uUXh_eEsaxeX9bx5BGdHh-ODIe-nK_ASUVrLZaaUUd5nCDks7VSRlujQ0AIWMlEOaaUMjShtFluvhFG5M3nhIxnFWeJDKx_DoKor9wSYsgjSfG4S46mbe5gp6XKRurCwqRTOB_B2tcN6tmyiobvkt8z0kh8a-aE7fmgZwD4xYf0mNcDuHtTzC93rk47pjqxK45IwFdqkDKFkKW1khJHWiDSA3RULda-Vjb6WoQBersmoT7RrReXqRfcOzWNGZBTA9pLj65VQK3ry-QGkG7KwsdRNSjWddD270adQyjWAdyupuV7Wv7di5_9_8QJuD8dfT_TJ59HxU7gjSKipsWy6C4N2vnDPEC-15nmvFL8A9Q4Pcw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BViAuFc8SKGAkDiCwNrGd1wnRx1IoWlWllXqz4tju7qHJsslW4t8zk81utbyumUhxPK9vPOMZgDdRZJGzaP3SApUcI4acFy4ueZEV6Dx94iLXFciOk6Nz9fUivujrn5q-rHJlEztDbeuSzsiHgsbkYkCVp0Pfl0WcHIw-zn5wmiBFmdZ-nMZt2EKvGIoBbO0djk9O1yculNNSUd7fnAllNmzQe9ENM0HzPTDQ4HLDO3VN_P-GPP8soPwti9o5p9F92O5RJfu0FIMHcMtVD-HOcs7kz0dQozCwY35aNG8_R-LgHZ9Wk6mZUn6dzaisxSL5O48z1ixmXWWsa9glBujthNWeXdGJvGP7ZyJh1OSajCR-rSSBmTM6-ucWBfnaWdYurup58xjOR4dn-0e8n7TAS0RsLZeZUkZ5nyH8sLRTRVqic0NrWMhEOaSVMjSitFlsvRJG5c7khY9kFGeJD618AoOqrtxTYMoiYPO5SYynzu5hpqTLRerCwqZSOB_A-9UO69myoYbuEuEy00t-aOSH7vihZQB7xIT1m9QMu3tQzy91r1s6pvuyKo1LwldonzKElaW0kRFGWiPSAHZXLNS9hjb6Rp4CeL0mo27RrhWVqxfdOzSbGVFSADtLjq9XQm3pyf8HkG7IwsZSNynVdNL170b_QunXAD6spOZmWf_eimf__4tXcBf1QX_7Mj5-DvcEyTT1mE13YdDOF-4FQqfWvOx14hfZ_BOg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+K-Ras%28G12D%29-inhibitory+peptide+KS-58+suppresses+growth+of+murine+CT26+colorectal+cancer+cell-derived+tumors&rft.jtitle=Scientific+reports&rft.au=Sakamoto%2C+Kotaro&rft.au=Lin%2C+Bangzhong&rft.au=Nunomura%2C+Kazuto&rft.au=Izawa%2C+Takeshi&rft.date=2022-05-17&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-022-12401-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_022_12401_3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon